GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Firebrick Pharma Ltd (ASX:FRE) » Definitions » Total Current Liabilities

Firebrick Pharma (ASX:FRE) Total Current Liabilities : A$0.29 Mil (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Firebrick Pharma Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Firebrick Pharma's total current liabilities for the quarter that ended in Jun. 2024 was A$0.29

Firebrick Pharma Total Current Liabilities Historical Data

The historical data trend for Firebrick Pharma's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Firebrick Pharma Total Current Liabilities Chart

Firebrick Pharma Annual Data
Trend Jun21 Jun22 Jun23 Jun24
Total Current Liabilities
0.22 0.45 0.51 0.29

Firebrick Pharma Semi-Annual Data
Jun22 Dec22 Jun23 Dec23 Jun24
Total Current Liabilities 0.45 0.50 0.51 0.36 0.29

Firebrick Pharma Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Firebrick Pharma's Total Current Liabilities for the fiscal year that ended in Jun. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=0.149+0
+Other Current Liabilities+Current Deferred Liabilities
=0.142+0
=0.29

Firebrick Pharma's Total Current Liabilities for the quarter that ended in Jun. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=0.149+0
+Other Current Liabilities+Current Deferred Liabilities
=0.142+0
=0.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Firebrick Pharma Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Firebrick Pharma's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Firebrick Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Firebrick Pharma Ltd (ASX:FRE) » Definitions » Total Current Liabilities
Comparable Companies
XKRX:054300 XKRX:112610 XKRX:378340 XKRX:317830 XKRX:340930 XKRX:372170 XKRX:071670 XKRX:010660 XKRX:058610 XKRX:370090 LLY JNJ MRK ABBV XSWX:ROG LSE:AZN XSWX:NOVN PFE AMGN XPAR:SAN
Traded in Other Exchanges
N/A
Address
440 Collins Street, Level 10, Melbourne, VIC, AUS, 3000
Website
https://www.firebrickpharma.com
Firebrick Pharma Ltd is an Australian pharmaceutical developer. It is engaged in the development and commercialization of povidone-iodine (PVP-I) products under the Nasodine brand. Its Nasodine Nasal Spray which is in the commercialization phase, is a broad-spectrum anti-viral spray, designed to be an effective treatment and prevention of respiratory viral infections such as the common cold. In parallel, the company is also engaged in the development of the follow-on Nasodine brand products.

Firebrick Pharma Headlines

No Headlines